Table 1 Clinical characteristics of the patients in the training and validation sets used to construct the nomogram, according to the in-hospital mortality status
Clinical characteristics | Training set (n = 1169) | Validation set (n = 316) | ||||
|---|---|---|---|---|---|---|
|  | In-hospital mortality (n = 95) | Survival (n = 1074) | P | In-hospital mortality (n = 25) | Survival (n = 291) | P |
Male | 60 (63.2) | 816 (76.0) | 0.006* | 18 (72.0) | 207 (71.1) | 0.927 |
Age (years) | 66.3 ± 13.3 | 59.6 ± 11.4 |  < 0.001* | 66.0 ± 14.2 | 60.0 ± 12.1 | 0.298 |
BMI (kg/m2) | 25.0 ± 3.9 | 25.5 ± 3.3 | 0.011* | 25.5 ± 4.0 | 25.4 ± 3.4 | 0.077 |
Drinking history | 22 (23.2) | 297 (27.7) | 0.346 | 8 (32.0) | 68 (23.4) | 0.332 |
Smoking history | 35 (36.8) | 518 (48.2) | 0.033* | 8 (32.0) | 121 (41.6) | 0.350 |
DM history | 26 (27.4) | 214 (19.9) | 0.085 | 7 (28.0) | 59 (20.3) | 0.362 |
Hypertension history | 51 (53.7) | 516 (48.0) | 0.292 | 10 (40.0) | 139 (47.8) | 0.455 |
Killip classification |  |  |  < 0.001* |  |  |  < 0.001* |
 I | 35 (36.8) | 939 (87.4) |  | 12 (48.0) | 262 (90.0) |  |
 II | 14 (14.7) | 110 (10.2) |  | 5 (20.0) | 21 (7.2) |  |
 III | 8 (8.4) | 18 (1.7) |  | 1 (4.0) | 6 (2.1) |  |
 IV | 38 (40.0) | 7 (0.7) |  | 7 (28.0) | 2 (0.7) |  |
LMCAD | 7 (7.4) | 3 (0.3) |  < 0.001* | 2 (8.0) | 1 (0.3) |  < 0.001* |
Grading of thrombus | Â | Â | 0.005* | Â | Â | 0.340 |
 0 | 0 | 6 (0.6) |  | 0 | 2 (0.7) |  |
 1 | 0 | 15 (1.4) |  | 3 (12.0) | 5 (1.7) |  |
 2 | 2 (2.1) | 96 (8.9) |  | 3 (12.0) | 32 (11.0) |  |
 3 | 29 (30.5) | 450 (41.9) |  | 6 (24.0) | 131 (45.0) |  |
 4 | 44 (46.3) | 348 (32.4) |  | 10 (40.0) | 94 (32.3) |  |
 5 | 20 (21.1) | 159 (14.8) |  | 3 (12.0) | 42 (14.4) |  |
TIMI classification |  |  |  < 0.001* |  |  |  < 0.001* |
 0 | 16 (16.8) | 1 (0.1) |  | 6 (24.0) | 0 |  |
 1 | 10 (10.2) | 2 (0.2) |  | 3 (12.0) | 1 (0.3) |  |
 2 | 12 (12.6) | 57 (5.3) |  | 2 (8.0) | 15 (5.1) |  |
 3 | 57 (60.0) | 1014 (94.4) |  | 14 (56.0) | 275 (94.5) |  |
Slow flow | 41 (43.2) | 86 (8.0) |  < 0.001* | 7 (28.0) | 25 (8.6) |  < 0.001* |
Application of IABP | 18 (19.0) | 14 (1.3) |  < 0.001* | 4 (16.0) | 3 (1.0) |  < 0.001* |
Administration of β-blocker | 32 (33.7) | 809 (75.3) |  < 0.001* | 6 (24.0) | 236 (81.1) |  < 0.001* |
ACEI/ARB | 20 (21.1) | 644 (60.0) |  < 0.001* | 5 (20.0) | 186 (63.9) | 0.003* |
Symptom-to-door time (min) | 256 ± 235 | 89 ± 73 |  < 0.001* | 248 ± 226 | 85 ± 74 |  < 0.001* |
Symptom-to-balloon time (min) | 426 ± 244 | 236 ± 153 |  < 0.001* | 420 ± 269 | 234 ± 157 |  < 0.001* |
Syntax score | 29.3 ± 9.9 | 20.7 ± 7.7 | 0.003* | 31.9 ± 13.1 | 20.9 ± 7.9 | 0.003* |
EF (%) | 47.2 ± 8.5 | 54.6 ± 8.1 | 0.918 | 45.1 ± 7.4 | 54.7 ± 7.64 | 0.926 |
CK-MB (U/L) | 180.0 ± 157.2 | 156.4 ± 58.2 |  < 0.001* | 175.3 ± 197.5 | 158.9 ± 54.7 | 0.019* |
Random blood glucose (mmol/L) | 9.25 ± 3.51 | 8.06 ± 2.83 | 0.056 | 9.3 (7.4,15.71) | 7.1 (6.19,9.28) | 0.001* |
Triglycerides (mmol/L) | 1.42 (1.01,1.80) | 1.43 (0.99,1.99) | 0.687 | 1.28 (0.98,1.71) | 1.49 (0.99,1.99) | 0.290 |